Black patients with diabetic macular edema demonstrated significantly less visual acuity improvement following intravitreal bevacizumab treatment than did white and Hispanic patients, according to a study.
“This is an important finding because diabetic macular edema is twice as likely to affect Black individuals than white individuals,” study co-author Manju L. Subramanian, MD, told Healio/OSN.
The retrospective cohort study directly examined race and ethnicity as a factor impacting DME treatment response to Avastin (bevacizumab, Genentech).
Researchers evaluated percentage of
Uncategorized